Últimas noticias sobre Steris (NYSE:STE) Bolsa

Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Steris PLC

Stream Media Corp

Santech Holdings Limited - American Depositary Shares

Santech Holdings Ltd

Scatec ASA

STEER Technologies Inc Ordinary Shares

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

Majestic Dragon AeroTech Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Step Finance - United States Dollar

STERLING CHECK CORP COM

Lido stETH

Stevia Corp

SRH Total Return Fund, Inc.

Piper Sandler analyst Jason Bednar maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $260 to $265.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Steris, Raises Price Target to $265

WIIM

STERIS shares are trading higher. The company announced outcomes from the ethylene oxide trial.

The Court declared a mistrial at Plaintiff's request during jury deliberations when dismissal of one of the jurors reduced the jury to fewer than twelve. The Court will schedule the case for re-trial at a later date.
Isomedix intends to continue to vigorously defend against allegations regarding ethylene oxide operations and emissions from the Waukegan, Illinois facility during 2005 to 2008. Deploying its own rigorous best practices, Isomedix has regularly invested in its facilities and has created processes and procedures that meet or exceed the applicable environmental regulatory standards.

Legal

STERIS Announces That Trial Against Isomedix Ended In A Mistrial On Jan. 17; Court To Schedule Case For Re-Trial At Later Date

In the latest quarter, 4 analysts provided ratings for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $262.5, along with a high estimate of $265.00 and a low estimate of $260.00. Surpassing the previous average price target of $252.50, the current average has increased by 3.96%.
<img src="https://www.benzinga.com/files/images/story/2024/1731952859_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Steris is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Steris's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>Get to Know Steris Better</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Understanding the Numbers: Steris's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 7.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.32%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.36, Steris adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Steris Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.

Needham Reiterates Hold on Steris

Steris shares are trading lower after the company reported worse-than-expected Q2 revenue results

Stephens &amp; Co. analyst Jacob Johnson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $260 price target.

Stephens & Co. Reiterates Overweight on Steris, Maintains $260 Price Target

Guidance

Steris Reiterates FY25 As Reported Revenue To Increase 6.5-7.5%, Adj EPS From Continuing Operations To Be $9.05 - $9.25, Est $9.16

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent. The company reported quarterly sales of $1.33 billion which met the analyst consensus estimate. This is a 1.04 percent decrease over sales of $1.34 billion the same period last year.

Earnings

Earnings Beats

Steris Q2 2025 Sales $1.328B, Miss $1.33B Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent.

Steris Q2 2025 Adj EPS $2.14 Beats $2.12 Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Steris to report an earnings per share (EPS) of $2.12.
Steris bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 2.36% drop in the share price the following trading session.
Here's a look at Steris's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.98</td>
<td>2.38</td>
<td>2.17</td>
<td>2.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.03</td>
<td>2.58</td>
<td>2.22</td>
<td>2.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730836886_0.png" alt="eps graph" />
<h3>Performance of Steris Shares</h3>
Shares of Steris were trading at $225.82 as of November 04. Over the last 52-week period, shares are up 10.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/STE/earnings">To track all earnings releases for Steris visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Steris

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>KGI Securities analyst Terry Lee upgraded Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Neutral to Outperform and announced a $276 price target. Tesla shares closed at $213.65 on Wednesday. <a href="https://www.benzinga.com/quote/tsla/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Matt O&#8217;Connor upgraded the rating for Regions Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) from Hold to Buy and increased the price target from $24 to $26. Regions Finl shares closed at $23.64 on Wednesday. <a href="https://www.benzinga.com/quote/RF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730076/mark-strouse">JP Morgan analyst Mark Strouse</a> upgraded NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Underweight to Neutral but lowered the price target from $25 to $22. NextEra Energy Partners shares closed at $21.01 on Wednesday. <a href="https://www.benzinga.com/quote/NEP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e8b4df71e7bd60001d9d077/jason-bednar">Piper Sandler analyst Jason Bednar</a> upgraded STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and boosted the price target from $230 to $260. Steris shares closed at $221.15 on Wednesday. <a href="https://www.benzinga.com/quote/STE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Bascome Majors upgraded the rating for Canadian Pacific Kansas City Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) from Neutral to Positive but slashed the price target from $94 to $92. Canadian Pacific Kansas shares closed at $78.83 on Wednesday. <a href="https://www.benzinga.com/quote/CP/analyst-ratings">See how other analysts view this stock.</a> </li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png" alt="" class="wp-image-612833" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243.png 1228w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41517173/eaton-transdigm-and-a-big-bank-on-cnbcs-final-trades">Eaton, TransDigm And A Big Bank On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>

Upgrades

Markets

Trading Ideas

TSLA

This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

STERIS shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $230 to $260.

4 analysts have expressed a variety of opinions on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $262.5, with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is apparent, with the current average reflecting a 3.96% increase from the previous average price target of $252.50.
<img src="https://www.benzinga.com/files/images/story/2024/1729778431_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Steris's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Steris's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Breaking Down Steris's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Steris's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.12%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Steris

Piper Sandler analyst Jason Bednar upgrades Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and raises the price target from $230 to $260.

Piper Sandler Upgrades Steris to Overweight, Raises Price Target to $260

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Tuesday.</a>
Constellation Brands has revised its FY25 comparable EPS forecast to $13.60 &#8211; $13.80, compared to the previous forecast of $13.50 &#8211; $13.80. This is compared to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the $13.70 estimate.</a>
Constellation Brands projects FY25 reported EPS in the range of $3.05 &#8211; $7.92, down from the previous forecast of $14.63 &#8211; $14.93 and well below the $14.62 estimate.
The company anticipates a hefty non-cash goodwill impairment loss of around $1.5 billion to $2.5 billion for its Wine and Spirits division in the second quarter of fiscal 2025, which is factored into the revised reported&nbsp;EPS outlook.
The company also revised its Enterprise net sales growth forecast to 4% &#8211; 6% (from 6% &#8211; 7% prior), citing incremental macroeconomic headwinds affecting consumers, particularly unemployment and prolonged inventory destocking in wine and spirits markets.
The company updated Beer net sales growth to 6% &#8211; 8%&nbsp;(from 7% &#8211; 9% prior) and Wine and Spirits net sales outlook to (6)% &#8211; (4)% (from (0.5)% &#8211; 0.5% prior).
&#8220;While ongoing macroeconomic headwinds, particularly rising unemployment, have led to a recent deceleration in the rate of growth of consumer demand for our products, we are on track to deliver a solid mid single-digit volume increase this fiscal year for our Beer Business,&#8221; said Constellation Brands President and Chief Executive Officer Bill&nbsp;Newlands.
&#8220;These trends have been most notable in the top five states for our Beer Business, which account for just over half of our volumes; however, we continue to see volume growth within the low to mid single-digit range in these states and within the high single-digit range on average across the rest of the country.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/23/05/32347463/steris-delivered-strong-q4-performance-but-analyst-call-fy24-outlook-mixed" rel="noreferrer noopener">Steris Delivered Strong Q4 Performance, But Analyst Call FY24 Outlook Mixed</a>
The CEO noted that improvements from earlier initiatives benefit major brands in the Wine and Spirits sector, although category challenges continue to impact the fiscal year outlook.
Despite these challenges, the company has outpaced the CPG sector growth by nearly 3 percentage points in dollar sales and its Beer Business has achieved notable gains, including being the top dollar share gainer in its category and the third largest in the Beverage industry.
RBC Capital analyst Nik Modi reaffirms Constellation Brands with an Outperform rating and maintains a $308 price target.
Price Action: STZ shares are sharing higher by 3.08% to $248.12 at last check Tuesday.
Photo: Engin Akyurt from Pixabay.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i" target="_blank" rel="noreferrer noopener">Tesla's China Rivals Report Steady August Sales Performance Amid Intense Price Competition: What Investors Should Know</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Movers

General

What's Going On With Constellation Brands Stock Today?

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $263.75, along with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is evident, with the current average reflecting a 0.96% increase from the previous average price target of $261.25.
<img src="https://www.benzinga.com/files/images/story/2024/1725379219_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Steris among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Steris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>Discovering Steris: A Closer Look</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Steris displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.12%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin excels beyond industry benchmarks, reaching 11.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Steris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.39.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Steris Stands With Analysts

Keybanc analyst Brett Fishbin maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $255 to $265.

Keybanc Maintains Overweight on Steris, Raises Price Target to $265

A new SEC filing reveals that CHRISTOPHER HOLLAND, Board Member at Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), made a notable insider purchase on August 12,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001757898/000162828024036792//Archives/edgar/data/1757898/000162828024036792/0001628280-24-036792-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that HOLLAND purchased 988 shares of Steris. The total transaction amounted to $236,803. 
Monitoring the market, Steris's shares down by 0.0% at $233.94 during Tuesday's morning.
<h3>Get to Know Steris Better</h3>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 8.12% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 44.74%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Steris's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.46.
</li>
</ul>
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 41.41 is lower than the industry average, implying a discounted valuation for Steris's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.44, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 18.19 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001757898">Check Out The Full List Of Steris's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Move: CHRISTOPHER HOLLAND Invests $236K In Steris Stock

Dividend Champion, Contender, And Challenger Highlights: Week Of November 17

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Benitec Biopharma (B...

Analysts Are Bullish on These Healthcare Stocks: Steris (STE), Benitec Biopharma (BNTC)

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

Invesco Health Care Fund Q3 2024 Commentary

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing patient care. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Given the industry's bright prospects, investors could consider investing in sound healthcare technology stocks Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>), which are revolutionizing patient care.
The healthcare industry is undergoing rapid transformation owing to the pandemic, shifting demographics, rapid technological advancements, and rising patient expectations. As a result, healthcare companies are increasingly investing in and <a href="https://mobidev.biz/blog/technology-trends-healthcare-digital-transformation">adapting digital technologies</a> to maintain their competitive edge and offer the best solutions to patients.
Concrete technologies like telemedicine, AI-enabled medical devices, and blockchain electronic health records are <a href="https://www.digitalauthority.me/resources/state-of-digital-transformation-healthcare/">entirely reshaping healthcare processes and operations</a>. These modernized technologies, along with offering operational capabilities, also help companies reduce their costs, enhance operational efficiency, and mitigate other risks.
Blockchain technologies, AI, and the Internet of Things (IoT) have significantly impacted the healthcare sector along with emerging devices and infrastructures that are helping doctors, healthcare organizations, and patients gain immediate access to healthcare information, resulting in better decision-making and treatment options.
Fortune Business Insights projects the global healthcare IT market to grow to $981.23 billion by 2032, <a href="https://www.fortunebusinessinsights.com/healthcare-it-market-109359">exhibiting a CAGR of 15.4%</a>, driven by healthcare information technology opportunities like improving clinical outcomes, reducing human error, improving practice efficiencies, and facilitating care coordination.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, starting with the third choice.
Stock #3: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. It designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products. It also offers robotic, surgical, and bone cement products.
On November 25, ZBH announced U.S. FDA Premarket Approval Application (PMA) supplement approval for the Oxford&#xAE; Cementless Partial Knee. The partial knee allows surgeons to perform a PKR with improved fixation, better long-term implant survival rate, and improved efficiency in the operating room compared to the Oxford cemented partial knee procedure.
The Oxford cementless partial knee is now the only FDA-approved cementless partial knee implant in the U.S. This marked a revolutionary step offering patients a better range of motion, a more natural feel, and a more stable implant-to-bone fixation.
Also, on November 18, ZBH received the CE Mark certification for its Persona&#xAE; revision knee system. The addition to the Persona segment instills ZBH's commitment to personalized solutions, offering surgeons advanced tools for revision knee arthroplasty.
For the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. The company's adjusted <a href="https://www.investopedia.com/terms/o/operating_profit.asp">operating profit</a> grew 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH amounted to $353.20 million or $1.74 per common share, up 1.9% and 5.5% year-over-year, respectively.
In addition, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
According to the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% and 4%. It also expects adjusted EPS in the $7.95 - $8.05 range.
Street expects ZBH's revenue and EPS for the fourth quarter (ending December 2024) to increase 3.9% and 4.3% year-over-year to $2.02 billion and $2.30, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
ZBH's stock has increased 7.7% over the past month to close the last trading session at $112.02.
ZBH's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #26 out of 138 stocks.
<a href="https://stocknews.com/stock/ZBH/">Click here</a> to access additional ratings of ZBH for Momentum, Sentiment, and Stability.
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE offers infection prevention products and services worldwide. The company operates in three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, and other equipment.
On October 30, STE declared the distribution of a quarterly interim dividend of $0.57 per share. The dividend is to be paid on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.
With 14 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 1.06% at the current share price. Its four-year average dividend yield is 0.86%. And the company's dividend payouts have increased at a 9.5% CAGR over the past three years.
STE's total revenues increased 7.3% year-over-year to $1.33 billion for the third quarter that ended September 30, 2024. The company's gross profit grew 6% from the year-ago value to $578.79 million. Net income attributable to stockholders came in at $150.03 million and $1.51 per share, indicating growth of 30.1% and 30.2% year-over-year, respectively.
Analysts expect STE's revenue for the first quarter (ending June 2025) to grow 6.5% year-over-year to $1.36 billion. For the same quarter, its EPS is expected to increase 12.5% year-over-year to $2.28. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
STE's shares have gained 8% over the past year to close the last trading session at $217.47.
STE's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Sentiment. Within the Medical – Devices &amp; Equipment industry, STE is ranked #12 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have STE ratings for Value, Growth, Quality, and Momentum. Get all STE ratings <a href="https://stocknews.com/stock/STE/">here</a>.
Stock #1: Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>)
TCMD is a medical technology company that develops and provides medical devices to treat underserved chronic diseases. The company offers Flexitouch Plus system and Entre Plus System. It also has a mobile application, Kylee, which helps patients learn about lymphedema.
On October 2, TCMD launched Nimbl&#x2122;, its next-generation pneumatic compression platform for the treatment of upper extremity lymphedema. Nimbl is significantly smaller and lighter than previous device iterations and is indicated for treating patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing.
This important portfolio addition reflects TCMD's commitment to advancing solutions that increase patient access to therapy with a differentiated user experience.
TCMD reported total revenue of $73.09 million, up 5% year-over-year during the third quarter that ended June 30, 2024, and its non-GAAP gross profit grew 10.9% from the year-ago value to $55.10 million. The company's adjusted EBITDA of $10.72 million indicates a growth of 39.3% from the prior year's quarter.
Furthermore, the company's net income came in at $5.16 million and $0.21 per common share for the quarter, respectively.
Street expects TCMD's revenue for the second quarter (ending June 2025) to increase 9.2% year-over-year to $79.95 million, and its EPS for the same period is expected to grow 16.6% year-over-year to $0.23. Also, the company has topped the consensus EPS estimate in three of the trailing four quarters.
Shares of TCMD have surged 49.3% over the past six months and 34.9% over the past year to close the last trading session at $18.93.
TCMD's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
TCMD has an A grade for Value and a B for Quality. The stock is ranked #6 among the 138 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have TCMD ratings for Growth, Sentiment, Momentum, and Stability. Get all TCMD ratings <a href="https://stocknews.com/stock/TCMD/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $112.02 per share on Thursday morning, up $1.38 (+1.25%). Year-to-date, ZBH has declined -7.37%, versus a 27.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-ste-tcmd-3-healthcare-technology-companies-revolutionizing-patient-care/>3 Healthcare Technology Companies Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Technology Companies Revolutionizing Patient Care

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Steris (STE – Research Report), with a price target of $260....

Piper Sandler Reaffirms Their Buy Rating on Steris (STE)

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

Steris (STE) announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix Operations, a subsidiary of the company, en...

Steris announces outcome of ethylene oxide trial

Steris declares $0.57 dividend

ACHC

ALLE

AMAT

AMCR

AMGN

AMZN

APLO

ARTNA

AVGO

BBIO

BCPC

BKLN

BNTC

BOTJ

BPMC

BPOP

BSVN

BWXT

CABO

CARR

CBAN

CBRE

CBSH

CCBG

CCOI

CDNA

CHCT

CINF

CIVB

CLVT

CQQQ

CRNX

CSGS

CTSH

DXCM

ENSG

EPRT

ERIE

EVRG

EXPO

FANG

FAST

FBIZ

FBMS

FCBC

FCPT

FELE

FMCB

FRME

FSBW

FXNC

GABC

GMED

GOLF

HFWA

HSIC

HTHT

INVH

IRTC

ISRG

JBHT

JJSF

JKHY

KBWB

KBWD

KBWY

KFRC

KLIC

LAND

LCII

LFUS

LMAT

LSTR

MBWM

MCHP

MEDP

MELI

MKTX

MMSI

MSBI

MSFT

NDAQ

NIDB

NRIM

NTNX

ODFL

OFLX

OLED

OTEX

PCEF

PDBC

PHAT

PNQI

PRFZ

PRGO

QCOM

QQQJ

QQQM

RBCAA

REGN

RELY

RSPT

SAMG

SBFG

SBSI

SCHW

SEIC

SIRI

SOPH

SOXQ

SPGP

Comments

Steris

Noticias

Últimas noticias sobre Steris (NYSE:STE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL